在中低收入国家获得药物和开展临床试验。
Access to medications and conducting clinical trials in LMICs.
机构信息
Division of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Observatory 7925, Cape Town, South Africa.
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, PO Box 2616, Saxonwold 2132, South Africa.
出版信息
Nat Rev Nephrol. 2015 Mar;11(3):189-94. doi: 10.1038/nrneph.2015.6. Epub 2015 Feb 10.
Access to essential medications is limited in many low-to-middle income countries (LMICs) and those that are available may be prohibitively expensive to the general population. Clinical trials have been suggested as an approach to improve drug access in LMICs but the number of trials conducted in these countries is small because of regulatory issues and a lack of infrastructure. In this article, Nature Reviews Nephrology asks three experts their opinions on how to improve drug access and increase the numbers of clinical trials conducted in LMICs.
在许多中低收入国家（LMICs），基本药物的可及性受到限制，而那些可用的药物对于普通民众来说可能过于昂贵。有人建议开展临床试验，以改善 LMICs 的药物可及性，但由于监管问题和基础设施缺乏，在这些国家开展的临床试验数量很少。在这篇文章中，《自然评论：肾病学》采访了三位专家，询问他们对如何改善药物可及性以及增加在 LMICs 开展临床试验数量的看法。
Zotero 插件